6 news items
Genmab Completes Acquisition of ProfoundBio
GMAB
21 May 24
.Contact: Marisol Peron, Senior Vice President, Global Communications & Corporate AffairsT: +1 609 524 0065; E
FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
GMAB
PFE
29 Apr 24
. "This full approval opens up new treatment paths for this patient community who have long faced limited options
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
GMAB
PFE
29 Apr 24
and Founder and Chief Visionary Officer, Cervivor, Inc. "This full approval opens up new treatment paths for this patient community who have long faced
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
GMAB
PFE
29 Apr 24
Visionary Officer, Cervivor, Inc. "This full approval opens up new treatment paths for this patient community who have long faced limited options
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
GMAB
3 Apr 24
: Marisol Peron, Senior Vice President, Global Communications & Corporate AffairsT: +1 609 524 0065; E
2gx b1v2ashnldrrod09ylxtjbe
GMAB
26 Mar 24
: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations
- Prev
- 1
- Next